Axon Enterprise (AXON) 10-Q 6 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	TASER INTERNATIONAL INC
Entity Central Index Key	1,069,183
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		53,881,744

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 40,354	$ 48,367
Short-term investments	46,252	32,774
Accounts and notes receivable, net of allowance of $250 and $251 as of June 30, 2015 and December 31, 2014, respectively	25,753	30,735
Inventory, net	23,687	18,323
Prepaid expenses and other current assets	10,068	4,443
Deferred income tax assets, net	5,186	5,186
Total current assets	151,300	139,828
Property and equipment, net of accumulated depreciation of $34,881 and $33,906 as of June 30, 2015 and December 31, 2014, respectively	18,231	17,523
Deferred income tax assets, net	10,398	10,877
Intangible assets, net	7,085	3,115
Goodwill	7,786	2,206
Long-term investments	12,377	9,296
Other assets	4,976	2,523
Total assets	212,153	185,368
Current liabilities:
Accounts payable	7,477	7,682
Accrued liabilities	6,605	9,245
Current portion of deferred revenue	16,249	14,020
Customer deposits	1,322	988
Current portion of capital lease payable	40	38
Total current liabilities	31,693	31,973
Deferred revenue, net of current portion	22,725	21,668
Liability for unrecognized tax benefits	1,152	1,471
Long-term deferred compensation	1,739	1,121
Long-term contingent consideration	950	0
Long-term portion of capital lease payable	9	29
Total liabilities	$ 58,268	$ 56,262
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of June 30, 2015 and December 31, 2014	$ 0	$ 0
Common stock, $0.00001 par value; 200,000,000 shares authorized; 53,865,918 and 53,000,867 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	1	1
Additional paid-in capital	174,015	162,641
Treasury stock at cost, 18,139,958 shares as of June 30, 2015 and December 31, 2014	(114,645)	(114,645)
Retained earnings	94,353	81,045
Accumulated other comprehensive income	161	64
Total stockholders’ equity	153,885	129,106
Total liabilities and stockholders’ equity	$ 212,153	$ 185,368

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance on accounts receivable	$ 250	$ 251
Accumulated depreciation	$ 34,881	$ 33,906
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	53,865,918	53,000,867
Common stock, shares outstanding	53,865,918	53,000,867
Treasury stock, shares	18,139,958	18,139,958

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Net sales	$ 46,713	$ 37,175	$ 91,475	$ 73,360
Cost of products sold and services delivered	15,990	13,961	30,884	27,938
Gross margin	30,723	23,214	60,591	45,422
Operating expenses:
Sales, general and administrative	15,443	13,547	30,008	27,293
Research and development	5,906	3,455	10,464	7,061
Total operating expenses	21,349	17,002	40,472	34,354
Income from operations	9,374	6,212	20,119	11,068
Interest and other income, net	99	42	34	72
Income before provision for income taxes	9,473	6,254	20,153	11,140
Provision for income taxes	3,370	2,370	6,845	3,865
Net income	$ 6,103	$ 3,884	$ 13,308	$ 7,275
Net income per common and common equivalent shares:
Basic (in dollars per share)	$ 0.11	$ 0.07	$ 0.25	$ 0.14
Diluted (in dollars per share)	$ 0.11	$ 0.07	$ 0.24	$ 0.13
Weighted average number of common and common equivalent shares outstanding:
Basic (in shares)	53,644	53,383	53,407	53,287
Diluted (in shares)	54,800	54,755	54,662	54,928
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 6,103	$ 3,884	$ 13,308	$ 7,275
Foreign currency translation adjustments	8	5	97	15
Comprehensive income	$ 6,111	$ 3,889	$ 13,405	$ 7,290

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income	$ 13,308	$ 7,275
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,362	2,267
Loss on write-down / disposal of property and equipment, net	0	17
Loss on disposal of intangibles	165	126
Bond premium amortization	826	428
Change in provision for doubtful accounts	(44)	84
Change in provision for excess and obsolete inventory	(85)	15
Change in provision for warranty expense	(19)	426
Stock-based compensation	3,223	2,684
Deferred income taxes	(511)	7,910
Unrecognized tax benefits	(319)	(1,257)
Excess tax benefit from stock-based compensation	(6,245)	(5,516)
Change in assets and liabilities:
Accounts and notes receivable	5,613	(663)
Inventory	(5,244)	(4,017)
Prepaid expenses and other assets	(8,174)	(3,689)
Accounts payable, accrued and other liabilities	3,646	(3,282)
Deferred revenue	3,133	3,920
Customer deposits	334	(766)
Net cash provided by operating activities	10,969	5,962
Cash flows from investing activities:
Purchases of investments	(38,750)	(17,312)
Proceeds from call / maturity of investments	21,365	4,200
Purchases of property and equipment	(1,770)	(1,222)
Purchases of intangible assets	(201)	(109)
Business acquisition, net of cash acquired	7,840
Net cash used in investing activities	(27,196)	(14,443)
Cash flows from financing activities:
Repurchase of common stock	0	(19,552)
Proceeds from options exercised	2,553	7,372
Payroll tax payments for net-settled stock awards	(647)	(1,190)
Payments on capital lease obligation	(18)	(18)
Excess tax benefit from stock-based compensation	6,245	5,516
Net cash provided by (used in) financing activities	8,133	(7,872)
Effect of exchange rate changes on cash and cash equivalents	81	25
Net decrease in cash and cash equivalents	(8,013)	(16,328)
Cash and cash equivalents, beginning of period	48,367	42,271
Cash and cash equivalents, end of period	40,354	25,943
Supplemental disclosure:
Cash paid for income taxes, net	4,848	367
Non-cash transactions
Property and equipment purchases in accounts payable and accrued liabilities	$ 205	$ 75

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies TASER International, Inc. (“TASER” or the “Company”) is a developer and manufacturer of advanced conducted electrical weapons (“CEWs”) designed for use by law enforcement, military, corrections, and private security personnel, and by private individuals for personal defense. In addition, the Company has developed full technology solutions for the capture, storage and management of video/audio evidence as well as other tactical capabilities for use in law enforcement. The Company sells its products worldwide through its direct sales force, distribution partners, online store and third-party resellers. The Company was incorporated in Arizona in September 1993, and reincorporated in Delaware in January 2001. The Company’s corporate headquarters and manufacturing facilities are located in Scottsdale, Arizona. The Company’s software development unit facility is located in Seattle, Washington. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries, including TASER International Europe SE (“TASER Europe”), TASER International B.V., and MediaSolv Solutions Corporation ("MediaSolv"). All material intercompany accounts, transactions, and profits have been eliminated. a. Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended December 31, 2014 , as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Form 10-K for the year ended December 31, 2014 . The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: • product warranty reserves, • inventory valuation reserves, • accounts receivable reserves, • revenue recognition allocated in multiple-deliverable contracts or arrangements, • valuation of goodwill, intangibles and long-lived assets, • recognition, measurement and valuation of current and deferred income taxes, • projection of future taxable income in both United States and foreign jurisdictions for estimating consolidated income tax expense, • fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, and • recognition and measurement of contingencies and accrued litigation expense. Actual results could differ materially from those estimates. b. Segment Information The Company is comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business which includes the TASER Cam, Axon cameras and related accessories, Evidence.com and revenues generated by MediaSolv (the “Axon” segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the Chief Operating Decision Maker (the “CODM”) for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 13. c. Geographic Information and Major Customers For the three and six months ended June 30, 2015 and 2014 , net sales by geographic area were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 United States $ 38,695 82.8 % $ 32,155 86.5 % $ 74,196 81.1 % $ 57,731 78.7 % Other Countries 8,018 17.2 5,020 13.5 17,279 18.9 15,629 21.3 Total $ 46,713 100.0 % $ 37,175 100.0 % $ 91,475 100.0 % $ 73,360 100.0 % Sales to customers outside of the U.S. are typically denominated in U.S. dollars, and are attributed to each country based on the shipping address of the distributor or customer. For the three and six months ended June 30, 2015 and 2014 , no individual country outside the U.S. represented more than 10% of net sales. Sales in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of the Company's customers. For the three and six months ended June 30, 2015 and 2014 , no customer represented more than 10% of total net sales. At June 30, 2015 there were no outstanding customer balances representing more than 10% of the aggregate accounts receivable balance. At December 31, 2014 , the Company had a trade receivable from one unaffiliated customer comprising 13.4% of the aggregate accounts receivable balance. d. Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator for basic and diluted earnings per share: Net income $ 6,103 $ 3,884 $ 13,308 $ 7,275 Denominator: Weighted average shares outstanding - basic 53,644 53,383 53,407 53,287 Dilutive effect of stock-based awards 1,156 1,372 1,255 1,641 Diluted weighted average shares outstanding 54,800 54,755 54,662 54,928 Anti-dilutive stock-based awards excluded 153 361 173 309 Net income per common share: Basic $ 0.11 $ 0.07 $ 0.25 $ 0.14 Diluted $ 0.11 $ 0.07 $ 0.24 $ 0.13 e. Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable The Company derives revenue from two primary sources: (1) the sale of physical products, including CEWs, Axon cameras, corresponding extended warranties, and related accessories such as E-docks, cartridges and batteries, among others, and (2) subscription to the Company's Evidence.com software as a service ("SaaS") (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other professional services revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract. Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price. The Company offers the right to purchase extended warranties that include additional services and coverage beyond the limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years. Evidence.com and Axon cameras and related accessories have stand-alone value to the customer and are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of Evidence.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. The Company recognizes revenue for the Axon hardware at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for Evidence.com is deferred at the time of the sale and recognized over the service period. In certain circumstances, not all requirements are met for the recognition of revenue relative to equipment sold in conjunction with Evidence.com at the time the equipment is provided to customers. In such circumstances, based on limitations associated with the allocation of arrangement consideration, part of the revenue for the equipment may be recognized ratably over the specified term of the contract, or when all conditions for revenue recognition are met, if sooner. In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally at the end of the contract period. The Company recently launched the Officer Safety Plan (“OSP”) whereby a customer enters into a five year Evidence.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of the Axon devices every 2.5 years , and includes a TASER CEW at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the Axon and CEW devices over the five-year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of Axon cameras and related accessories at inception along with annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered. Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training and professional service revenues are recorded as the services are provided. Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 5 for further disclosures about the Company’s deferred revenue. Sales are typically made on credit, and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition, and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best use of estimates, and is based on judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions. The Company may, from time to time, enter into agreements with its customers to finance their purchases with a note receivable that may range in terms up to five years. Sales are recorded at the fair value of the note, which is generally sold and assigned to a third-party financing company. The terms of the assignments are such that the Company expects to receive payment within 30 days of the original sale. The assignments are non-recourse and the Company has no obligations or continuing involvement with the notes receivable. Prior to entering into an assignment, the Company evaluates the credit quality and financial condition of the third-party financing company. The Company does not generally record interest income on notes receivable due to minimal holding periods, nor has the Company recognized significant gains or losses upon the assignment of the notes. As of June 30, 2015 the Company had an outstanding balance of $0.1 million related to such arrangements, and as of December 31, 2014 no such balances existed. f. Standard Warranties The Company warranties its CEWs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying condensed consolidated balance sheets. Changes in the Company’s estimated product warranty liabilities are as follows (in thousands): Six Months Ended June 30, 2015 2014 Balance, beginning of period $ 675 $ 955 Utilization of accrual (200 ) (303 ) Warranty (recovery) expense (19 ) 426 Balance, end of period $ 456 $ 1,078 g. Fair Value of Financial Instruments The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: • Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. • Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. • Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability. The Company has cash equivalents and investments, which at June 30, 2015 and December 31, 2014 were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of June 30, 2015 and December 31, 2014 was $1.7 million and $1.1 million , respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the accompanying condensed consolidated balance sheets. h. Valuation of Goodwill, Intangibles and Long-lived Assets Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. The Company recorded losses on disposal of intangible assets of $0.2 million and $0.1 million during the six months ended June 30, 2015 and 2014, respectively. i. Recently Issued Accounting Guidance In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, ASU 2014-09 provides for the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") Topic No. 605, “Revenue Recognition,” most industry-specific guidance throughout the industry topics of the ASC, and some cost guidance related to construction-type and production-type contracts. ASU 2014-09 is effective for public entities for annual periods and interim periods within those annual periods beginning after December 15, 2016. In July 2015, the FASB voted to amend ASU 2014-09 by proposing a one-year deferral of the effective date as well as providing the option to early adopt the standard on the original effective date. The Company is currently evaluating the timing of its adoption and the impact of adopting the new revenue standard on its consolidated financial statements. In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, “Compensation—Stock Compensation” (“ASC 718”), as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (i) prospectively to all awards granted or modified after the effective date; or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements, however does not expect there to be a material impact at this time. In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330)" ("ASU 2015-11"). The amendments require that an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements, however does not expect there to be a material impact at this time. j. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Cash, Cash Equivalents and Inve

Cash, Cash Equivalents and Investments	6 Months Ended
	Jun. 30, 2015
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at June 30, 2015 and December 31, 2014 (in thousands): As of June 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 37,225 $ — $ — $ 37,225 $ 37,225 $ — $ — Level 1: Money market funds 2,649 — — 2,649 2,649 — — Corporate bonds 34,478 — (53 ) 34,425 — 30,038 4,440 Subtotal 37,127 — (53 ) 37,074 2,649 30,038 4,440 Level 2: State and municipal obligations 20,276 19 (3 ) 20,292 480 13,500 6,296 Certificates of deposit 4,355 — — 4,355 — 2,714 1,641 Subtotal 24,631 19 (3 ) 24,647 480 16,214 7,937 Total $ 98,983 $ 19 $ (56 ) $ 98,946 $ 40,354 $ 46,252 $ 12,377 As of December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 44,260 $ — $ — $ 44,260 $ 44,260 $ — $ — Level 1: Money market funds 3,932 — — 3,932 3,932 — — Corporate bonds 20,388 — (34 ) 20,354 — 15,656 4,732 Subtotal 24,320 — (34 ) 24,286 3,932 15,656 4,732 Level 2: State and municipal obligations 19,145 18 — 19,163 175 15,891 3,079 Certificates of deposit 2,712 — — 2,712 — 1,227 1,485 Subtotal 21,857 18 — 21,875 175 17,118 4,564 Total $ 90,437 $ 18 $ (34 ) $ 90,421 $ 48,367 $ 32,774 $ 9,296 The Company believes the unrealized losses on the Company’s investments are due to interest rate fluctuations. As these investments are either short-term in nature, are expected to be redeemed at par value, and/or because the Company has the ability and intent to hold these investments to maturity, the Company does not consider these investments to be other than temporarily impaired at June 30, 2015 . The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at June 30, 2015 by contractual maturity (in thousands): Amortized Cost Fair Value Due in less than one year $ 46,252 $ 46,216 Due after one year, through two years 12,377 12,376 Due after two years — — Total short-term and long-term investments $ 58,629 $ 58,592

Inventory

Inventory	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Inventory Inventories are stated at the lower of cost or market. Cost is determined using the weighted average cost of raw materials which approximates the first-in, first-out (“FIFO”) method and includes allocations of manufacturing labor and overhead. Provisions are made to reduce potentially excess, obsolete or slow-moving inventories to their net realizable value. Inventories consisted of the following at June 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Raw materials $ 13,355 $ 12,229 Work-in-process 119 111 Finished goods 11,759 7,337 Reserve for excess and obsolete inventory (1,546 ) (1,354 ) Total inventory $ 23,687 $ 18,323

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The changes in the carrying amount of goodwill for the six months ended June 30, 2015 were as follows (in thousands): Balance, beginning of period $ 2,206 Goodwill acquired 5,580 Balance, end of period $ 7,786 Intangible assets (other than goodwill) consisted of the following (in thousands): June 30, 2015 December 31, 2014 Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortized: Domain names 5 years $ 125 $ (120 ) $ 5 $ 125 $ (114 ) $ 11 Issued patents 4-15 years 1,842 (613 ) 1,229 1,759 (549 ) 1,210 Issued trademarks 3-11 years 594 (222 ) 372 566 (205 ) 361 Customer relationships 4 years 310 (12 ) 298 — — — Non-compete agreements 4 years 350 (13 ) 337 — — — Developed technology 7 years 3,470 (76 ) 3,394 — — — Total amortized 6,691 (1,056 ) 5,635 2,450 (868 ) 1,582 Not amortized: TASER trademark 900 900 900 900 Patents and trademarks pending 550 550 633 633 Total not amortized 1,450 1,450 1,533 1,533 Total intangible assets $ 8,141 $ (1,056 ) $ 7,085 $ 3,983 $ (868 ) $ 3,115 Amortization expense relative to intangible assets for the three months ended June 30, 2015 and 2014 was approximately $150,000 and $42,000 , respectively. Amortization expense relative to intangible assets for the six months ended June 30, 2015 and 2014 was approximately $211,000 and $81,000 , respectively. Estimated amortization for intangible assets with definitive lives for the remaining six months of 2015 , the next five years ended December 31, and thereafter, is as follows (in thousands): 2015 (remaining six months) $ 426 2016 846 2017 842 2018 829 2019 709 2020 646 Thereafter 1,337 Total $ 5,635

Deferred Revenue

Deferred Revenue	6 Months Ended
	Jun. 30, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	Deferred Revenue Deferred revenue consisted of the following (in thousands): June 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total Warranty: TASER Weapons $ 6,722 $ 12,757 $ 19,479 $ 6,591 $ 13,809 $ 20,400 Axon 1,464 1,913 3,377 679 894 1,573 8,186 14,670 22,856 7,270 14,703 21,973 Hardware: TASER Weapons 951 1,073 2,024 365 753 1,118 Axon 665 3,897 4,562 491 2,643 3,134 1,616 4,970 6,586 856 3,396 4,252 Axon Services 6,145 3,085 9,230 5,717 3,569 9,286 Other 302 — 302 177 — 177 Total $ 16,249 $ 22,725 $ 38,974 $ 14,020 $ 21,668 $ 35,688 June 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total TASER Weapons $ 7,975 $ 13,830 $ 21,805 $ 7,133 $ 14,562 $ 21,695 Axon 8,274 8,895 17,169 6,887 7,106 13,993 Total $ 16,249 $ 22,725 $ 38,974 $ 14,020 $ 21,668 $ 35,688

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consisted of the following at June 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Accrued salaries and benefits $ 2,580 $ 3,699 Accrued judgments and settlements 80 108 Accrued professional fees 228 257 Accrued warranty expense 456 675 Accrued income and other taxes 663 539 Other accrued expenses 2,598 3,967 Accrued liabilities $ 6,605 $ 9,245

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Deferred Tax Assets Net deferred income tax assets at June 30, 2015 , include capitalized research and development costs, research and development tax credits, non-qualified stock-based compensation expense, deferred warranty revenue, warranty and inventory reserves, accrued vacation, and other items, partially offset by accelerated depreciation expense. The Company’s total current and long-term net deferred tax assets at June 30, 2015 were $15.6 million . In preparing the Company’s condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating the Company’s ability to recover its deferred income tax assets, management considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining its provisions for income taxes, its deferred tax assets and liabilities, and its future taxable income for purposes of assessing its ability to utilize any future tax benefit from its deferred tax assets. Although management believes that its tax estimates are reasonable, the ultimate tax determination involves significant judgments that could become subject to audit by tax authorities in the ordinary course of business. As of each reporting date, management considers new evidence, both positive and negative, that could impact management’s view with regards to future realization of deferred tax assets. As of June 30, 2015 , the Company continues to demonstrate three-year cumulative pre-tax income in the U.S. federal and Arizona tax jurisdictions; however, the Arizona R&D Tax Credits start to expire in 2018 with a significant tranche with a gross value of $1.2 million expiring if not used by the end of 2019. Under the Company’s new tax structure, it appears that long term investments which impact short term profits will likely result in some of the R&D credits expiring before they are utilized. Therefore, management has concluded that it is more likely than not that a portion of the Company’s deferred tax assets will not be realized. The Company has completed research and development (“R&D”) tax credit studies which identified approximately $10.5 million in tax credits for federal, Arizona and California income tax purposes related to the 2003 through 2015 tax years. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $2.8 million as of June 30, 2015 . In addition, management accrued approximately $0.2 million for estimated uncertain tax positions related to certain state income tax liabilities. The Company recently completed an IRS audit for the tax year 2012, and as of June 30, 2015, the amount of unrecognized tax benefits decreased by $0.4 million . The Company does not expect a significant increase or decrease in the total amount of unrecognized tax benefits within 12 months. Should the total unrecognized tax benefit of $3.0 million be recognized, the Company’s effective tax rate would be favorably impacted. Approximately $1.2 million of the unrecognized tax benefit associated with research and development credits has been netted against the research and development credit deferred tax asset. Effective Tax Rate The Company’s overall effective tax rate for the six months ended June 30, 2015 , after discrete period adjustments, was 34.0% . Before discrete adjustments the tax rate was 36.6% , which is below the statutory rate primarily due to the impact of the domestic production activities deduction, as well as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, but also increased by the impact of state taxes and non-deductible expenses for items such as ISO stock option expense, meals and entertainment, and lobbying fees. The Company has nearly completed the full implementation of its new international structure, which is new for 2015. In accounting for the income tax effects of this new structure, the Company has recognized income tax expense in the current quarter based on the results it expects for the full year. Actual results could be different, impacting the Company’s income tax expense in future quarters. The Company has chosen this method, from among those available to it, because of its expectation that it will produce the least amount of variability during the year.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity In May 2013, the Company’s stockholders approved a new stock incentive plan authorizing an additional 1.6 million shares, plus remaining available shares under a prior plan for issuance under the new plan. Combined with the legacy stock incentive plans, there are approximately 1.3 million shares available for grant as of June 30, 2015 . Performance-based stock awards The Company has issued performance-based stock options and performance-based restricted stock units ("RSUs"), the vesting of which is contingent upon the achievement of certain performance criteria related to the operating performance of the Company, as well as successful and timely development and market acceptance of future product introductions. In addition, certain of the performance RSUs have additional service requirements subsequent to the achievement of the performance criteria. Compensation expense is recognized over the implicit service period (the longer of the period the performance condition is expected to be achieved or the required service period) based on management’s estimate of the probability of the performance criteria being satisfied, adjusted at each balance sheet date. Restricted Stock Units The following table summarizes RSU activity for the six months ended June 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Units Weighted Average Grant-Date Fair Value Aggregate Units outstanding, beginning of year 1,226 $ 13.23 Granted 368 27.44 Released (364 ) 11.14 Forfeited (47 ) 15.70 Units outstanding, end of period 1,183 18.18 $ 39,411 Aggregate intrinsic value represents the Company’s closing stock price on the last trading day of the period, which was $33.31 per share, multiplied by the number of RSUs outstanding. As of June 30, 2015 , there was $17.5 million in unrecognized compensation costs related to RSUs under the Company's stock plans. The Company expects to recognize the cost related to the RSUs over a weighted average period of 2.85 years . RSUs are released when vesting requirements are met. During the six months ended June 30, 2015 , the Company granted approximately 36,101 performance-based RSUs, which are included in the table above. As of June 30, 2015 , the performance criteria had not been met for any of the 0.1 million performance-based RSUs outstanding. Certain of the performance-based RSUs granted in 2015 and 2014 contain provisions whereby the amount of RSUs that ultimately vest is dependent upon the level of achievement of performance metrics. The amount of RSUs included in the table above related to such grants is the target level, which is the Company's best estimate of the amount of RSUs that will vest. The maximum additional number of performance-based RSUs that could be earned is 0.1 million , which are not included in the table above. Certain RSUs that vested in the six months ended June 30, 2015 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld were approximately 25,000 and had a value of approximately $0.6 million on their respective vesting dates as determined by the Company’s closing stock price. Payments for the employees’ tax obligations are reflected as a financing activity within the statement of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the amount of shares that would have otherwise been issued as a result of the vesting. Stock Option Activity The following table summarizes stock option activity for the six months ended June 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Options outstanding, beginning of year 1,641 $ 5.26 Granted — — Exercised (500 ) 4.96 Expired / terminated (8 ) 8.71 Options outstanding, end of period 1,133 5.35 3.87 $ 31,685 Options exercisable, end of period 1,101 5.37 3.88 30,772 Options expected to vest, end of period 26 4.75 3.61 750 Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's common stock of $33.31 on June 30, 2015 . The intrinsic value of options exercised for the six months ended June 30, 2015 and 2014 was $13.2 million and $12.6 million , respectively. Options expected to vest are presented net of forfeitures. As of June 30, 2015 , total options outstanding includes approximately 0.2 million performance-based stock options, of which approximately 30,600 were unvested and 25,000 expected to vest. Stock-based Compensation Expense The estimated fair value of stock-based awards is amortized to expense on a straight-line basis over the service periods. As stock-based compensation expense recognized is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Cost of products sold and services delivered $ 89 $ 65 $ 159 $ 88 Sales, general and administrative expenses 925 948 1,858 1,658 Research and development expenses 665 494 1,206 938 Total stock-based compensation $ 1,679 $ 1,507 $ 3,223 $ 2,684 Stock Repurchase Plan In May 2014, the Company announced that TASER’s Board of Directors authorized a stock repurchase program to acquire up to $30.0 million of the Company’s outstanding common stock subject to stock market conditions and corporate considerations. There were no stock repurchase transactions during the six months ended June 30, 2015 . During the three months ended June 30, 2014, the Company purchased 1.5 million common shares under this program for a total cost of approximately $19.6 million , or a weighted average cost of $13.16 per share. The weighted average cost includes the average price paid per share of $13.13 , plus any applicable administrative costs for the transaction. As of June 30, 2015 , $7.6 million remains available under the plan for future purchases.

Line of Credit

Line of Credit	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Line of Credit	Line of Credit The Company has a $10.0 million revolving line of credit with a domestic bank. At both June 30, 2015 and December 31, 2014 , there were no borrowings under the line. As of June 30, 2015 , the Company had letters of credit outstanding of approximately $3.0 million under the facility and available borrowing of approximately $7.0 million . The line is secured by substantially all of the assets of the Company, and bears interest at varying rates (currently LIBOR plus 1.5% or Prime less 0.75% ). The line of credit matures on July 31, 2016 , and requires monthly payments of interest only. The Company’s agreement with the bank requires it to comply with certain financial and other covenants including maintenance of a maximum leverage ratio and minimum fixed charge coverage ratio. The leverage ratio (ratio of total liabilities to tangible net worth) can be no greater than 1 :1, and the fixed charge coverage ratio can be no less than 1.25 :1, based upon a trailing twelve -month period. At June 30, 2015 , the Company’s tangible net worth ratio was 0.42 :1 and its fixed charge coverage ratio was 2.81 :1. Accordingly, the Company was in compliance with these covenants.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Product Litigation The Company is currently named as a defendant in 12 lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CEW was used (or present) by law enforcement officers in connection with arrests or during training exercises. In addition, one other product litigation matter in which the Company is involved is currently on appeal. While the facts vary from case to case, the product liability claims are typically based on an alleged product defect resulting in injury or death, usually involving a failure to warn, and the plaintiffs are seeking monetary damages. Three recent lawsuits allege fraud and misrepresentation and are seeking punitive damages in addition to compensatory damages. The information throughout this note is current through the filing date of this Quarterly Report on Form 10-Q. As a general rule, it is the Company’s policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to the Company. Also, on occasion, the Company’s insurance company has settled such lawsuits over the Company’s objection where the risk is over the Company’s liability insurance deductibles. Due to the confidentiality of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, the Company does not identify or comment on which specific lawsuits have been settled or the amount of any settlement. In 2009, the Company implemented new risk management strategies, including revisions to product warnings and training to better protect both the Company and its customers from litigation based on ‘failure to warn’ theories - which comprise the vast majority of the cases against the Company. These risk management strategies have been highly effective in reducing the rate and exposure from litigation post-2009. From the third quarter of 2011 to the second quarter of 2015 , product liability cases have been reduced from 55 active to 13 active cases. Management believes that pre-2009 cases have a different risk profile than cases which have occurred since the risk management procedures were introduced in 2009. Therefore, the Company necessarily treats certain pre-2009 cases as exceptions to the Company’s general no settlement policy in order to reduce caseload, legal costs and liability exposure. The Company intends to continue its successful practice of aggressively defending and generally not settling litigation except in very limited and unusual circumstances as described above. With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter. Plaintiff Month Served Jurisdiction Claim Type Status Koon Dec-08 17th Judicial Circuit Court, Broward County, FL Training Injury Discovery Phase Derbyshire Nov-09 Ontario, Canada Superior Court of Justice Officer Injury Discovery Phase Thompson Mar-10 11th Judicial Circuit Court, Miami-Dade County, FL Suspect Injury During Arrest Discovery Phase - Trial scheduled November 2015 Doan Apr-10 The Queen's Bench Alberta, Red Deer Judicial Dist. Wrongful Death Discovery Phase Shymko Dec-10 The Queen's Bench, Winnipeg Centre, Manitoba Wrongful Death Pleading Phase Ramsey Jan-12 17th Judicial Circuit Court, Broward County, FL Wrongful Death Discovery Phase Firman Apr-12 Ontario, Canada Superior Court of Justice Wrongful Death Pleading Phase Schrock Sep-14 San Bernardino County Superior Court, CA Wrongful Death Discovery Phase - Trial scheduled July 2016 Moore Nov-14 St. Louis County Circuit Court, MO Wrongful Death Pleading Phase Jones Jan-15 Los Angeles County Superior Court, CA Suspect Injury Discovery Phase - Trial scheduled April 2016 McKelvey Apr-15 US District Court, OR Wrongful Death Pleading Phase Price Jul-15 US District Court, OR Wrongful Death Pleading Phase In addition, other product litigation matters in which the Company is involved that are currently on appeal are listed below: Plaintiff Month Served Jurisdiction Claim Type Status Mitchell Apr-12 US District Court, ED MI Wrongful Death Notice of Appeal filed August 2014 Cases that were dismissed or judgment entered during the second quarter of 2015 and through the filing date of this Quarterly Report on Form 10-Q are listed in the table below. Cases that were dismissed or judgment entered in prior fiscal quarters are not included in this table. Plaintiff Month Served Jurisdiction Claim Type Status Ricks May-12 US District Court, WD LA Wrongful Death Motion for Directed Verdict granted The claims, and in some instances the defense, of each of these lawsuits have been submitted to the Company’s insurance carriers that maintained insurance coverage during the applicable periods. The Company continues to maintain product liability insurance coverage with varying limits and deductibles. The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions). Policy Year Policy Start Date Policy End Date Insurance Coverage Deductible Amount Defense Costs Covered Remaining Insurance Coverage Active Cases and Cases on Appeal 2004 12/1/2003 12/1/2004 $ 2.0 $ 0.1 N $ 2.0 n/a 2005 12/1/2004 12/1/2005 10.0 0.3 Y 7.0 n/a 2006 12/1/2005 12/1/2006 10.0 0.3 Y 3.7 n/a 2007 12/1/2006 12/1/2007 10.0 0.3 Y 8.0 n/a 2008 12/1/2007 12/15/2008 10.0 0.5 Y — Koon 2009 12/15/2008 12/15/2009 10.0 1.0 N 10.0 Derbyshire 2010 12/15/2009 12/15/2010 10.0 1.0 N 10.0 Thompson, Shymko, Doan 2011 12/15/2010 12/15/2011 10.0 1.0 N 10.0 n/a Jan-Jun 2012 12/15/2011 6/25/2012 7.0 1.0 N 7.0 Ramsey, Mitchell, Firman Jul-Dec 2012 6/25/2012 12/15/2012 12.0 1.0 N 12.0 n/a 2013 12/15/2012 12/15/2013 12.0 1.0 N 12.0 n/a 2014 12/15/2013 12/15/2014 11.0 4.0 N 11.0 Schrock, Moore 2015 12/15/2014 12/15/2015 10.0 5.0 N 10.0 Jones, McKelvey, Price General From time to time, the Company is notified that it may be a party to a lawsuit or that a claim is being made against it. It is the Company’s policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on the Company. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against the Company. In certain legal matters, we record a liability when losses are deemed probable and reasonably estimable. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, and the severity of any potential loss. We reevaluate and update our accruals as matters progress over time. Based on our assessment of outstanding litigation and claims as of June 30, 2015 , the Company has determined that it is not reasonably possible that these lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows. Off-Balance Sheet Arrangements Under certain circumstances, the Company uses letters of credit and surety bonds to guarantee its performance under various contracts, principally in connection with the installation and integration of its Axon cameras and related technologies. Certain of the Company's letters of credit contracts and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At June 30, 2015 , the Company had outstanding letters of credit of approximately $3.0 million . Of that amount, $2.7 million is expected to expire in May 2017 and $0.3 million is expected to expire in January 2017. Additionally, the Company had approximately $2.4 million of outstanding surety bonds at June 30, 2015 , with $2.2 million expiring in July 2018 and the remaining $0.2 million expected to be released during the third quarter of 2015 with the completion of the remaining contractual performance terms.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company engages Dr. Mark Kroll, a member of the Board of Directors, to provide consulting services. The expenses related to these services were approximately $65,000 and $41,000 for the three months ended June 30, 2015 and 2014 , respectively, and $112,000 and $71,000 for the six months ended June 30, 2015 and 2014 , respectively. At June 30, 2015 and December 31, 2014 , the Company had accrued liabilities of approximately $21,000 and $8,000 , respectively, related to these services. Additionally, the Company subscribes to a mobile collaboration software suite co-founded and managed by Bret Taylor, a member of the Board of Directors. The Company licenses the software for approximately $20,000 per quarter, and as of June 30, 2015 had deferred costs related to an annual subscription of approximately $80,000 . No such deferred costs were recorded at December 31, 2014 .

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans The Company has a defined contribution profit sharing 401 (k) plan for eligible employees, which is qualified under Sections 401 (a) and 401 (k) of the Internal Revenue Code of 1986, as amended. Employees are entitled to make tax-deferred contributions of up to the maximum allowed by law of their eligible compensation. The Company also has a non-qualified deferred compensation plan for certain executives, key employees and non-employee directors through which participants may elect to postpone the receipt and taxation of a portion of their compensation, including stock-based compensation, received from the Company. The non-qualified deferred compensation plan allows eligible participants to defer up to 80% of their base salary and up to 100% of other types of compensation. The plan also allows for (i) matching and discretionary employer contributions and (ii) the deferral of vested RSU awards. Employee deferrals are deemed 100% vested upon contribution. Distributions from the plan are made upon retirement, death, separation of service, specified date or upon the occurrence of an unforeseeable emergency. Distributions can be paid in a variety of forms from lump sum to installments over a period of years. Participants in the plan are entitled to select from a wide variety of investments available under the plan and are allocated gains or losses based upon the performance of the investments selected by the participant. All gains or losses are allocated fully to plan participants and the Company does not guarantee a rate of return on deferred balances. Assets related to this plan consist of corporate-owned life insurance contracts and are included in other assets in the condensed consolidated balance sheets. Participants have no rights or claims with respect to any plan assets and any such assets are subject to the claims of the Company’s general creditors. Contributions to the plans are made by both the employee and the Company. Company contributions are based on the level of employee contributions and are immediately vested. The Company’s matching contributions to the 401(k) plan for the three months ended June 30, 2015 and 2014 , were approximately $0.3 million and $0.2 million , respectively. The Company’s matching contributions to the 401(k) plan for the six months ended June 30, 2015 and 2014 , were approximately $0.6 million and $0.4 million , respectively. The Company expects to make contributions to the non-qualified deferred compensation plan related to the three and six months ended June 30, 2015 , of approximately $7,000 and $23,000 , respectively. Future matching or profit sharing contributions to the plans are at the Company’s sole discretion.

Segment Data

Segment Data	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Data	Segment Data The Company’s operations are comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business, which includes the TASER Cam, Axon products, Evidence.com, and revenue generated by MediaSolv (the “Axon” segment). The Company includes only revenues and costs directly attributable to the Axon segment in that segment. Included in Axon segment costs are: costs of sales for both products and services, overhead allocation based on direct labor, selling expense for the Axon sales team, Axon product management expenses, trade shows and related expenses, and research and development for products included in the Axon segment. All other costs are included in the TASER Weapons segment. The CODM does not review assets by segment as part of the financial information provided; therefore, no asset information is provided in the following tables. Information relative to the Company’s reportable segments is as follows (in thousands): Three Months Ended June 30, 2015 Three Months Ended June 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 37,825 $ 5,930 $ 43,755 $ 32,675 $ 3,593 $ 36,268 Service revenue — 2,958 2,958 — 907 907 Net sales 37,825 8,888 46,713 32,675 4,500 37,175 Cost of products sold 11,278 3,716 14,994 10,663 2,760 13,423 Cost of services delivered — 996 996 — 538 538 Gross margin 26,547 4,176 30,723 22,012 1,202 23,214 Sales, general and administrative 10,823 4,620 15,443 10,901 2,646 13,547 Research and development 1,077 4,829 5,906 793 2,662 3,455 Income (loss) from operations $ 14,647 $ (5,273 ) $ 9,374 $ 10,318 $ (4,106 ) $ 6,212 Purchase of property and equipment $ 188 $ 1,158 $ 1,346 $ 336 $ 87 $ 423 Purchase of intangible assets 35 116 151 42 — 42 Purchase of property and equipment and intangible assets in connection with business acquisition — 9,779 9,779 — — — Depreciation and amortization 556 189 745 990 115 1,105 Six Months Ended June 30, 2015 Six Months Ended June 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 76,166 $ 10,432 $ 86,598 $ 65,150 $ 6,631 $ 71,781 Service revenue — 4,877 4,877 — 1,579 1,579 Net sales 76,166 15,309 91,475 65,150 8,210 73,360 Cost of products sold 22,359 6,864 29,223 21,581 5,416 26,997 Cost of services delivered — 1,661 1,661 — 941 941 Gross margin 53,807 6,784 60,591 43,569 1,853 45,422 Sales, general and administrative 21,528 8,480 30,008 22,190 5,103 27,293 Research and development 2,267 8,197 10,464 1,610 5,451 7,061 Income (loss) from operations $ 30,012 $ (9,893 ) $ 20,119 $ 19,769 $ (8,701 ) $ 11,068 Purchase of property and equipment $ 535 $ 1,235 $ 1,770 $ 1,033 $ 189 $ 1,222 Purchase of intangible assets 81 120 201 109 — 109 Purchase of property and equipment and intangible assets in connection with business acquisition — 9,779 9,779 — — — Depreciation and amortization 1,086 276 1,362 2,068 199 2,267

Business Acquisition

Business Acquisition	6 Months Ended
	Jun. 30, 2015
Business Acquisition [Abstract]
Business Acquisition	Business Acquisition On May 5, 2015, the Company acquired all of the outstanding capital stock of MediaSolv Solutions Corporation, a Delaware corporation for a total purchase price of $8.8 million . The purchase price consisted primarily of cash, net of cash acquired and working capital adjustments, of $7.8 million and contingent consideration of $1.0 million representing potential earn-outs to former stockholders based on predetermined future financial metrics. The Company has also agreed to additional earn-out provisions and compensation adjustments totaling approximately $4.0 million based, in part, on predefined future financial metrics that are not included as part of the purchase price. MediaSolv primarily provides solutions for interview room video, CCTV and on premise digital evidence management. These products will connect with the Company's Axon on-officer cameras and, in some cases, its Evidence.com cloud platform, further enabling law enforcement to unify existing silos of digital media and evidence into a seamless workflow from capture to the courtroom. The acquisition will also allow the Company to leverage MediaSolv’s existing network and relationships to further strengthen its position in the market. The Company's purchase price allocation is preliminary and subject to revision as more detailed analyses are completed and additional information about fair value of assets and liabilities become available, including additional information relating to tax matters and finalization of the valuation of identifiable intangible assets. The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, are as follows (in thousands): Accounts receivable and other current assets $ 591 Inventory 35 Property and equipment 54 Intangible assets 4,145 Goodwill 5,580 Accounts payable and accrued liabilities (403 ) Deferred revenue (153 ) Deferred income tax liabilities, net (1,057 ) Total purchase price $ 8,792 The Company has assigned the goodwill to the Axon segment. Other identifiable definite lived intangible assets were assigned a total weighted average amortization period of 6.5 years . MediaSolv has been included in the Company's consolidated results of operations subsequent to the acquisition date. Pro forma results of operations for MediaSolv have not been presented because they are not material to the consolidated results of operations. In connection with the acquisition, the Company incurred and expensed costs of approximately $0.2 million , which included legal, accounting and other third-party expenses related to the transaction.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Business Acquisition On July 16, 2015, TASER International B.V., a wholly owned subsidiary of the Company, acquired all of the outstanding capital stock of Tactical Safety Responses Limited, a United Kingdom ("UK") corporation ("TSR"). TSR is the Company's licensed distributor of TASER CEWs and Axon cameras and related accessories in the UK. The purchase price consisted of $4.0 million cash at close, and additional amounts in the form of earn-outs, subject to the achievement of predefined performance metrics. The acquired entity will operate under the name Axon Public Safety UK. The acquisition will be accounted for in the third quarter of fiscal 2015 using the acquisition method in accordance with ASC 805, Business Combinations . Accordingly, the identifiable assets acquired and liabilities assumed will be measured at their acquisition-date fair value. Operating results will be included in the Company’s consolidated financial statements from the effective date of the acquisition. Stock Repurchases In August 2015, the Company repurchased approximately 0.3 million common shares under an existing stock repurchase program for a total cost of approximately $7.6 million , or a weighted average cost of $25.86 per share. The weighted average cost includes the average price paid per share of $25.83 , plus applicable administrative costs for the transactions. These repurchase transactions substantially exhausted the remaining available balance at June 30, 2015 under the stock repurchase program approved by the Board of Directors in May 2014.

Organization and Summary of S21

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended December 31, 2014 , as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Form 10-K for the year ended December 31, 2014 . The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: • product warranty reserves, • inventory valuation reserves, • accounts receivable reserves, • revenue recognition allocated in multiple-deliverable contracts or arrangements, • valuation of goodwill, intangibles and long-lived assets, • recognition, measurement and valuation of current and deferred income taxes, • projection of future taxable income in both United States and foreign jurisdictions for estimating consolidated income tax expense, • fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, and • recognition and measurement of contingencies and accrued litigation expense. Actual results could differ materially from those estimates.
Segment Information	Segment Information The Company is comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business which includes the TASER Cam, Axon cameras and related accessories, Evidence.com and revenues generated by MediaSolv (the “Axon” segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the Chief Operating Decision Maker (the “CODM”) for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 13.
Geographic Information and Major Customers	Geographic Information and Major Customers For the three and six months ended June 30, 2015 and 2014 , net sales by geographic area were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 United States $ 38,695 82.8 % $ 32,155 86.5 % $ 74,196 81.1 % $ 57,731 78.7 % Other Countries 8,018 17.2 5,020 13.5 17,279 18.9 15,629 21.3 Total $ 46,713 100.0 % $ 37,175 100.0 % $ 91,475 100.0 % $ 73,360 100.0 % Sales to customers outside of the U.S. are typically denominated in U.S. dollars, and are attributed to each country based on the shipping address of the distributor or customer. For the three and six months ended June 30, 2015 and 2014 , no individual country outside the U.S. represented more than 10% of net sales. Sales in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of the Company's customers.
Income per Common Share	Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method.
Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable	Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable The Company derives revenue from two primary sources: (1) the sale of physical products, including CEWs, Axon cameras, corresponding extended warranties, and related accessories such as E-docks, cartridges and batteries, among others, and (2) subscription to the Company's Evidence.com software as a service ("SaaS") (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other professional services revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract. Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price. The Company offers the right to purchase extended warranties that include additional services and coverage beyond the limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years. Evidence.com and Axon cameras and related accessories have stand-alone value to the customer and are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of Evidence.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. The Company recognizes revenue for the Axon hardware at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for Evidence.com is deferred at the time of the sale and recognized over the service period. In certain circumstances, not all requirements are met for the recognition of revenue relative to equipment sold in conjunction with Evidence.com at the time the equipment is provided to customers. In such circumstances, based on limitations associated with the allocation of arrangement consideration, part of the revenue for the equipment may be recognized ratably over the specified term of the contract, or when all conditions for revenue recognition are met, if sooner. In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally at the end of the contract period. The Company recently launched the Officer Safety Plan (“OSP”) whereby a customer enters into a five year Evidence.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of the Axon devices every 2.5 years , and includes a TASER CEW at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the Axon and CEW devices over the five-year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of Axon cameras and related accessories at inception along with annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered. Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training and professional service revenues are recorded as the services are provided. Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 5 for further disclosures about the Company’s deferred revenue. Sales are typically made on credit, and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition, and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best use of estimates, and is based on judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions. The Company may, from time to time, enter into agreements with its customers to finance their purchases with a note receivable that may range in terms up to five years. Sales are recorded at the fair value of the note, which is generally sold and assigned to a third-party financing company. The terms of the assignments are such that the Company expects to receive payment within 30 days of the original sale. The assignments are non-recourse and the Company has no obligations or continuing involvement with the notes receivable. Prior to entering into an assignment, the Company evaluates the credit quality and financial condition of the third-party financing company. The Company does not generally record interest income on notes receivable due to minimal holding periods, nor has the Company recognized significant gains or losses upon the assignment of the notes. As of June 30, 2015 the Company had an outstanding balance of $0.1 million related to such arrangements, and as of December 31, 2014 no such balances existed.
Standard Warranties	Standard Warranties The Company warranties its CEWs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying condensed consolidated balance sheets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: • Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. • Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. • Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability. The Company has cash equivalents and investments, which at June 30, 2015 and December 31, 2014 were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of June 30, 2015 and December 31, 2014 was $1.7 million and $1.1 million , respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the accompanying condensed consolidated balance sheets.
Valuation of Goodwill, Intangibles and Long-lived Assets	Valuation of Goodwill, Intangibles and Long-lived Assets Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, ASU 2014-09 provides for the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") Topic No. 605, “Revenue Recognition,” most industry-specific guidance throughout the industry topics of the ASC, and some cost guidance related to construction-type and production-type contracts. ASU 2014-09 is effective for public entities for annual periods and interim periods within those annual periods beginning after December 15, 2016. In July 2015, the FASB voted to amend ASU 2014-09 by proposing a one-year deferral of the effective date as well as providing the option to early adopt the standard on the original effective date. The Company is currently evaluating the timing of its adoption and the impact of adopting the new revenue standard on its consolidated financial statements. In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, “Compensation—Stock Compensation” (“ASC 718”), as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (i) prospectively to all awards granted or modified after the effective date; or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements, however does not expect there to be a material impact at this time.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Organization and Summary of S22

Organization and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Net Sales by Geographic Area	For the three and six months ended June 30, 2015 and 2014 , net sales by geographic area were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 United States $ 38,695 82.8 % $ 32,155 86.5 % $ 74,196 81.1 % $ 57,731 78.7 % Other Countries 8,018 17.2 5,020 13.5 17,279 18.9 15,629 21.3 Total $ 46,713 100.0 % $ 37,175 100.0 % $ 91,475 100.0 % $ 73,360 100.0 %
Weighted Average Number of Shares Outstanding and Income Per Share	The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator for basic and diluted earnings per share: Net income $ 6,103 $ 3,884 $ 13,308 $ 7,275 Denominator: Weighted average shares outstanding - basic 53,644 53,383 53,407 53,287 Dilutive effect of stock-based awards 1,156 1,372 1,255 1,641 Diluted weighted average shares outstanding 54,800 54,755 54,662 54,928 Anti-dilutive stock-based awards excluded 153 361 173 309 Net income per common share: Basic $ 0.11 $ 0.07 $ 0.25 $ 0.14 Diluted $ 0.11 $ 0.07 $ 0.24 $ 0.13
Summary of Changes in Estimated Product Warranty Liabilities	Changes in the Company’s estimated product warranty liabilities are as follows (in thousands): Six Months Ended June 30, 2015 2014 Balance, beginning of period $ 675 $ 955 Utilization of accrual (200 ) (303 ) Warranty (recovery) expense (19 ) 426 Balance, end of period $ 456 $ 1,078

Cash, Cash Equivalents and In23

Cash, Cash Equivalents and Investments (Tables)	6 Months Ended
	Jun. 30, 2015
Cash and Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type	The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at June 30, 2015 and December 31, 2014 (in thousands): As of June 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 37,225 $ — $ — $ 37,225 $ 37,225 $ — $ — Level 1: Money market funds 2,649 — — 2,649 2,649 — — Corporate bonds 34,478 — (53 ) 34,425 — 30,038 4,440 Subtotal 37,127 — (53 ) 37,074 2,649 30,038 4,440 Level 2: State and municipal obligations 20,276 19 (3 ) 20,292 480 13,500 6,296 Certificates of deposit 4,355 — — 4,355 — 2,714 1,641 Subtotal 24,631 19 (3 ) 24,647 480 16,214 7,937 Total $ 98,983 $ 19 $ (56 ) $ 98,946 $ 40,354 $ 46,252 $ 12,377 As of December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 44,260 $ — $ — $ 44,260 $ 44,260 $ — $ — Level 1: Money market funds 3,932 — — 3,932 3,932 — — Corporate bonds 20,388 — (34 ) 20,354 — 15,656 4,732 Subtotal 24,320 — (34 ) 24,286 3,932 15,656 4,732 Level 2: State and municipal obligations 19,145 18 — 19,163 175 15,891 3,079 Certificates of deposit 2,712 — — 2,712 — 1,227 1,485 Subtotal 21,857 18 — 21,875 175 17,118 4,564 Total $ 90,437 $ 18 $ (34 ) $ 90,421 $ 48,367 $ 32,774 $ 9,296
Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments	The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at June 30, 2015 by contractual maturity (in thousands): Amortized Cost Fair Value Due in less than one year $ 46,252 $ 46,216 Due after one year, through two years 12,377 12,376 Due after two years — — Total short-term and long-term investments $ 58,629 $ 58,592

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following at June 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Raw materials $ 13,355 $ 12,229 Work-in-process 119 111 Finished goods 11,759 7,337 Reserve for excess and obsolete inventory (1,546 ) (1,354 ) Total inventory $ 23,687 $ 18,323

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill for the six months ended June 30, 2015 were as follows (in thousands): Balance, beginning of period $ 2,206 Goodwill acquired 5,580 Balance, end of period $ 7,786
Intangible Assets Other than goodwill	Intangible assets (other than goodwill) consisted of the following (in thousands): June 30, 2015 December 31, 2014 Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortized: Domain names 5 years $ 125 $ (120 ) $ 5 $ 125 $ (114 ) $ 11 Issued patents 4-15 years 1,842 (613 ) 1,229 1,759 (549 ) 1,210 Issued trademarks 3-11 years 594 (222 ) 372 566 (205 ) 361 Customer relationships 4 years 310 (12 ) 298 — — — Non-compete agreements 4 years 350 (13 ) 337 — — — Developed technology 7 years 3,470 (76 ) 3,394 — — — Total amortized 6,691 (1,056 ) 5,635 2,450 (868 ) 1,582 Not amortized: TASER trademark 900 900 900 900 Patents and trademarks pending 550 550 633 633 Total not amortized 1,450 1,450 1,533 1,533 Total intangible assets $ 8,141 $ (1,056 ) $ 7,085 $ 3,983 $ (868 ) $ 3,115
Estimated Amortization Expense of Intangible Assets	Estimated amortization for intangible assets with definitive lives for the remaining six months of 2015 , the next five years ended December 31, and thereafter, is as follows (in thousands): 2015 (remaining six months) $ 426 2016 846 2017 842 2018 829 2019 709 2020 646 Thereafter 1,337 Total $ 5,635

Deferred Revenue (Tables)

Deferred Revenue (Tables)	6 Months Ended
	Jun. 30, 2015
Deferred Revenue Disclosure [Abstract]
Summary of Deferred Revenue	Deferred revenue consisted of the following (in thousands): June 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total Warranty: TASER Weapons $ 6,722 $ 12,757 $ 19,479 $ 6,591 $ 13,809 $ 20,400 Axon 1,464 1,913 3,377 679 894 1,573 8,186 14,670 22,856 7,270 14,703 21,973 Hardware: TASER Weapons 951 1,073 2,024 365 753 1,118 Axon 665 3,897 4,562 491 2,643 3,134 1,616 4,970 6,586 856 3,396 4,252 Axon Services 6,145 3,085 9,230 5,717 3,569 9,286 Other 302 — 302 177 — 177 Total $ 16,249 $ 22,725 $ 38,974 $ 14,020 $ 21,668 $ 35,688 June 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total TASER Weapons $ 7,975 $ 13,830 $ 21,805 $ 7,133 $ 14,562 $ 21,695 Axon 8,274 8,895 17,169 6,887 7,106 13,993 Total $ 16,249 $ 22,725 $ 38,974 $ 14,020 $ 21,668 $ 35,688

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following at June 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Accrued salaries and benefits $ 2,580 $ 3,699 Accrued judgments and settlements 80 108 Accrued professional fees 228 257 Accrued warranty expense 456 675 Accrued income and other taxes 663 539 Other accrued expenses 2,598 3,967 Accrued liabilities $ 6,605 $ 9,245

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Restricted Stock Unit Activity	The following table summarizes RSU activity for the six months ended June 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Units Weighted Average Grant-Date Fair Value Aggregate Units outstanding, beginning of year 1,226 $ 13.23 Granted 368 27.44 Released (364 ) 11.14 Forfeited (47 ) 15.70 Units outstanding, end of period 1,183 18.18 $ 39,411
Summary of the Company's Stock Options Activity	The following table summarizes stock option activity for the six months ended June 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Options outstanding, beginning of year 1,641 $ 5.26 Granted — — Exercised (500 ) 4.96 Expired / terminated (8 ) 8.71 Options outstanding, end of period 1,133 5.35 3.87 $ 31,685 Options exercisable, end of period 1,101 5.37 3.88 30,772 Options expected to vest, end of period 26 4.75 3.61 750
Reported Share-Based Compensation	The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Cost of products sold and services delivered $ 89 $ 65 $ 159 $ 88 Sales, general and administrative expenses 925 948 1,858 1,658 Research and development expenses 665 494 1,206 938 Total stock-based compensation $ 1,679 $ 1,507 $ 3,223 $ 2,684

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Loss Contingencies	With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter. Plaintiff Month Served Jurisdiction Claim Type Status Koon Dec-08 17th Judicial Circuit Court, Broward County, FL Training Injury Discovery Phase Derbyshire Nov-09 Ontario, Canada Superior Court of Justice Officer Injury Discovery Phase Thompson Mar-10 11th Judicial Circuit Court, Miami-Dade County, FL Suspect Injury During Arrest Discovery Phase - Trial scheduled November 2015 Doan Apr-10 The Queen's Bench Alberta, Red Deer Judicial Dist. Wrongful Death Discovery Phase Shymko Dec-10 The Queen's Bench, Winnipeg Centre, Manitoba Wrongful Death Pleading Phase Ramsey Jan-12 17th Judicial Circuit Court, Broward County, FL Wrongful Death Discovery Phase Firman Apr-12 Ontario, Canada Superior Court of Justice Wrongful Death Pleading Phase Schrock Sep-14 San Bernardino County Superior Court, CA Wrongful Death Discovery Phase - Trial scheduled July 2016 Moore Nov-14 St. Louis County Circuit Court, MO Wrongful Death Pleading Phase Jones Jan-15 Los Angeles County Superior Court, CA Suspect Injury Discovery Phase - Trial scheduled April 2016 McKelvey Apr-15 US District Court, OR Wrongful Death Pleading Phase Price Jul-15 US District Court, OR Wrongful Death Pleading Phase
Summary of Other Product Litigation Matters	In addition, other product litigation matters in which the Company is involved that are currently on appeal are listed below: Plaintiff Month Served Jurisdiction Claim Type Status Mitchell Apr-12 US District Court, ED MI Wrongful Death Notice of Appeal filed August 2014
Summary of Cases Dismissed or Judgment Entered	Cases that were dismissed or judgment entered during the second quarter of 2015 and through the filing date of this Quarterly Report on Form 10-Q are listed in the table below. Cases that were dismissed or judgment entered in prior fiscal quarters are not included in this table. Plaintiff Month Served Jurisdiction Claim Type Status Ricks May-12 US District Court, WD LA Wrongful Death Motion for Directed Verdict granted
Information Regarding the Company's Insurance Coverage	The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions). Policy Year Policy Start Date Policy End Date Insurance Coverage Deductible Amount Defense Costs Covered Remaining Insurance Coverage Active Cases and Cases on Appeal 2004 12/1/2003 12/1/2004 $ 2.0 $ 0.1 N $ 2.0 n/a 2005 12/1/2004 12/1/2005 10.0 0.3 Y 7.0 n/a 2006 12/1/2005 12/1/2006 10.0 0.3 Y 3.7 n/a 2007 12/1/2006 12/1/2007 10.0 0.3 Y 8.0 n/a 2008 12/1/2007 12/15/2008 10.0 0.5 Y — Koon 2009 12/15/2008 12/15/2009 10.0 1.0 N 10.0 Derbyshire 2010 12/15/2009 12/15/2010 10.0 1.0 N 10.0 Thompson, Shymko, Doan 2011 12/15/2010 12/15/2011 10.0 1.0 N 10.0 n/a Jan-Jun 2012 12/15/2011 6/25/2012 7.0 1.0 N 7.0 Ramsey, Mitchell, Firman Jul-Dec 2012 6/25/2012 12/15/2012 12.0 1.0 N 12.0 n/a 2013 12/15/2012 12/15/2013 12.0 1.0 N 12.0 n/a 2014 12/15/2013 12/15/2014 11.0 4.0 N 11.0 Schrock, Moore 2015 12/15/2014 12/15/2015 10.0 5.0 N 10.0 Jones, McKelvey, Price

Segment Data (Tables)

Segment Data (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Summary of Operational Information Relative to the Company's Reportable Segments	Information relative to the Company’s reportable segments is as follows (in thousands): Three Months Ended June 30, 2015 Three Months Ended June 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 37,825 $ 5,930 $ 43,755 $ 32,675 $ 3,593 $ 36,268 Service revenue — 2,958 2,958 — 907 907 Net sales 37,825 8,888 46,713 32,675 4,500 37,175 Cost of products sold 11,278 3,716 14,994 10,663 2,760 13,423 Cost of services delivered — 996 996 — 538 538 Gross margin 26,547 4,176 30,723 22,012 1,202 23,214 Sales, general and administrative 10,823 4,620 15,443 10,901 2,646 13,547 Research and development 1,077 4,829 5,906 793 2,662 3,455 Income (loss) from operations $ 14,647 $ (5,273 ) $ 9,374 $ 10,318 $ (4,106 ) $ 6,212 Purchase of property and equipment $ 188 $ 1,158 $ 1,346 $ 336 $ 87 $ 423 Purchase of intangible assets 35 116 151 42 — 42 Purchase of property and equipment and intangible assets in connection with business acquisition — 9,779 9,779 — — — Depreciation and amortization 556 189 745 990 115 1,105 Six Months Ended June 30, 2015 Six Months Ended June 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 76,166 $ 10,432 $ 86,598 $ 65,150 $ 6,631 $ 71,781 Service revenue — 4,877 4,877 — 1,579 1,579 Net sales 76,166 15,309 91,475 65,150 8,210 73,360 Cost of products sold 22,359 6,864 29,223 21,581 5,416 26,997 Cost of services delivered — 1,661 1,661 — 941 941 Gross margin 53,807 6,784 60,591 43,569 1,853 45,422 Sales, general and administrative 21,528 8,480 30,008 22,190 5,103 27,293 Research and development 2,267 8,197 10,464 1,610 5,451 7,061 Income (loss) from operations $ 30,012 $ (9,893 ) $ 20,119 $ 19,769 $ (8,701 ) $ 11,068 Purchase of property and equipment $ 535 $ 1,235 $ 1,770 $ 1,033 $ 189 $ 1,222 Purchase of intangible assets 81 120 201 109 — 109 Purchase of property and equipment and intangible assets in connection with business acquisition — 9,779 9,779 — — — Depreciation and amortization 1,086 276 1,362 2,068 199 2,267

Business Acquisition (Tables)

Business Acquisition (Tables)	6 Months Ended
	Jun. 30, 2015
Business Acquisition [Abstract]
Schedule of Business Acquisitions, by Acquisition	The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, are as follows (in thousands): Accounts receivable and other current assets $ 591 Inventory 35 Property and equipment 54 Intangible assets 4,145 Goodwill 5,580 Accounts payable and accrued liabilities (403 ) Deferred revenue (153 ) Deferred income tax liabilities, net (1,057 ) Total purchase price $ 8,792

Organization and Summary of S32

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2015USD ($)SourceDistributor	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)Distributor
Summary Of Significant Accounting Policy [Line Items]
Number Of Distributers | Distributor	1		1
Accounts and notes receivable by customers one			13.40%
Number of revenue sources | Source	2
Company receive payment	30 days
Financing receivable	$ 0.1		$ 0
Warranty period	1 year
Corporate owned life insurance policies fair value	$ 1.7		$ 1.1
Goodwill and intangible asset impairment	$ 0.2	$ 0.1
Extended Product Warranty | Minimum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	1 year
Extended Product Warranty | Maximum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	5 years
Evidence. Com
Summary Of Significant Accounting Policy [Line Items]
Subscription period	5 years
Device upgrade period	2 years 6 months

Organization and Summary of S33

Organization and Summary of Significant Accounting Policies - Net Sales by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$ 46,713	$ 37,175	$ 91,475	$ 73,360
Percentage of Net sales by Geographic Area	100.00%	100.00%	100.00%	100.00%
United States
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$ 38,695	$ 32,155	$ 74,196	$ 57,731
Percentage of Net sales by Geographic Area	82.80%	86.50%	81.10%	78.70%
Other Countries
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$ 8,018	$ 5,020	$ 17,279	$ 15,629
Percentage of Net sales by Geographic Area	17.20%	13.50%	18.90%	21.30%

Organization and Summary of S34

Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator for basic and diluted earnings per share:
Net income	$ 6,103	$ 3,884	$ 13,308	$ 7,275
Denominator:
Weighted average shares outstanding—basic	53,644	53,383	53,407	53,287
Dilutive effect of stock-based awards (in shares)	1,156	1,372	1,255	1,641
Diluted weighted average shares outstanding	54,800	54,755	54,662	54,928
Anti-dilutive stock-based awards excluded	153	361	173	309
Net income (loss) per common share:
Basic (in dollars per share)	$ 0.11	$ 0.07	$ 0.25	$ 0.14
Diluted (in dollars per share)	$ 0.11	$ 0.07	$ 0.24	$ 0.13

Organization and Summary of S35

Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Product Warranty Liabilities (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance, beginning of period	$ 675	$ 955
Utilization of accrual	(200)	(303)
Warranty (recovery) expense	(19)	426
Balance, end of period	$ 456	$ 1,078

Cash, Cash Equivalents, and Inv

Cash, Cash Equivalents, and Investments - Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	$ 98,983	$ 90,437
Gross Unrealized Gains	19	18
Gross Unrealized Losses	(56)	(34)
Fair Value	98,946	90,421
Cash and Cash Equivalents	40,354	48,367
Short-term investments	46,252	32,774
Long-term investments	12,377	9,296
State and Municipal Obligations
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	20,276	19,145
Gross Unrealized Gains	19	18
Gross Unrealized Losses	(3)	0
Fair Value	20,292	19,163
Cash and Cash Equivalents	480	175
Short-term investments	13,500	15,891
Long-term investments	6,296	3,079
Certificates of Deposit
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	4,355	2,712
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	4,355	2,712
Cash and Cash Equivalents	0	0
Short-term investments	2,714	1,227
Long-term investments	1,641	1,485
Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	37,127	24,320
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(53)	(34)
Fair Value	37,074	24,286
Cash and Cash Equivalents	2,649	3,932
Short-term investments	30,038	15,656
Long-term investments	4,440	4,732
Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	24,631	21,857
Gross Unrealized Gains	19	18
Gross Unrealized Losses	(3)	0
Fair Value	24,647	21,875
Cash and Cash Equivalents	480	175
Short-term investments	16,214	17,118
Long-term investments	7,937	4,564
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	37,225	44,260
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	37,225	44,260
Cash and Cash Equivalents	37,225	44,260
Short-term investments	0	0
Long-term investments	0	0
Money Market Funds
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	2,649	3,932
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	2,649	3,932
Cash and Cash Equivalents	2,649	3,932
Short-term investments	0	0
Long-term investments	0	0
Corporate Bonds
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	34,478	20,388
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(53)	(34)
Fair Value	34,425	20,354
Cash and Cash Equivalents	0	0
Short-term investments	30,038	15,656
Long-term investments	$ 4,440	$ 4,732

Cash, Cash Equivalents, and I37

Cash, Cash Equivalents, and Investments - Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	$ 46,252	$ 32,774
Due after one year, through two years	12,377	$ 9,296
Amortized Cost
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	46,252
Due after one year, through two years	12,377
Due after two years	0
Total short-term and long-term investments	58,629
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	46,216
Due after one year, through two years	12,376
Due after two years	0
Total short-term and long-term investments	$ 58,592

Inventory (Detail)

Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 13,355	$ 12,229
Work-in-process	119	111
Finished goods	11,759	7,337
Reserve for excess and obsolete inventory	(1,546)	(1,354)
Total inventory	$ 23,687	$ 18,323

Goodwill and Intangible Asset39

Goodwill and Intangible Assets - Schedule of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Goodwill [Roll Forward]
Balance, beginning of period	$ 2,206
Goodwill acquired	5,580
Balance, end of period	$ 7,786

Goodwill and Intangible Asset40

Goodwill and Intangible Assets - Intangible Assets Other than Goodwill (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	$ 6,691	$ 2,450
Accumulated amortization	(1,056)	(868)
Total	5,635	1,582
Not amortized intangible assets, carrying amount	1,450	1,533
Intangible assets, gross carrying amount	8,141	3,983
Intangible assets, net carrying amount	7,085	3,115
TASER trademark
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized intangible assets, carrying amount	900	900
Patents and trademarks pending
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized intangible assets, carrying amount	$ 550	633
Domain names
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	5 years
Amortized intangible assets, gross carrying amount	$ 125	125
Accumulated amortization	(120)	(114)
Total	5	11
Issued patents
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	1,842	1,759
Accumulated amortization	(613)	(549)
Total	$ 1,229	1,210
Issued patents | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	4 years
Issued patents | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	15 years
Issued trademarks
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	$ 594	566
Accumulated amortization	(222)	(205)
Total	$ 372	361
Issued trademarks | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	3 years
Issued trademarks | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	11 years
Customer relationships
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	4 years
Amortized intangible assets, gross carrying amount	$ 310	0
Accumulated amortization	(12)	0
Total	$ 298	0
Non-compete agreements
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	4 years
Amortized intangible assets, gross carrying amount	$ 350	0
Accumulated amortization	(13)	0
Total	$ 337	0
Developed technology
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	7 years
Amortized intangible assets, gross carrying amount	$ 3,470	0
Accumulated amortization	(76)	0
Total	$ 3,394	$ 0

Goodwill and Intangible asset41

Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
2015 (remaining six months)	$ 426		$ 426
2,016	846		846
2,017	842		842
2,018	829		829
2,019	709		709
2,020	646		646
Thereafter	1,337		1,337
Total	5,635		5,635		$ 1,582
Amortization expense	$ 150	$ 42	$ 211	$ 81

Deferred Revenue - Summary of D

Deferred Revenue - Summary of Deferred Revenue (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 38,974	$ 35,688
Current portion of deferred revenue	16,249	14,020
Deferred revenue, net of current portion	22,725	21,668
Warranty
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	22,856	21,973
Current portion of deferred revenue	8,186	7,270
Deferred revenue, net of current portion	14,670	14,703
AXON services
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	9,230	9,286
Current portion of deferred revenue	6,145	5,717
Deferred revenue, net of current portion	3,085	3,569
Hardware equipment
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	6,586	4,252
Current portion of deferred revenue	1,616	856
Deferred revenue, net of current portion	4,970	3,396
Other
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	302	177
Current portion of deferred revenue	302	177
Deferred revenue, net of current portion	0	0
TASER Weapons
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	21,805	21,695
Current portion of deferred revenue	7,975	7,133
Deferred revenue, net of current portion	13,830	14,562
TASER Weapons | Warranty
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	19,479	20,400
Current portion of deferred revenue	6,722	6,591
Deferred revenue, net of current portion	12,757	13,809
TASER Weapons | Hardware equipment
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	2,024	1,118
Current portion of deferred revenue	951	365
Deferred revenue, net of current portion	1,073	753
Axon
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	17,169	13,993
Current portion of deferred revenue	8,274	6,887
Deferred revenue, net of current portion	8,895	7,106
Axon | Warranty
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	3,377	1,573
Current portion of deferred revenue	1,464	679
Deferred revenue, net of current portion	1,913	894
Axon | Hardware equipment
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	4,562	3,134
Current portion of deferred revenue	665	491
Deferred revenue, net of current portion	$ 3,897	$ 2,643

Accrued Liabilities (Detail)

Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued salaries and benefits	$ 2,580	$ 3,699
Accrued judgments and settlements	80	108
Accrued professional fees	228	257
Accrued warranty expense	456	675	$ 1,078	$ 955
Accrued income and other taxes	663	539
Other accrued expenses	2,598	3,967
Accrued liabilities	$ 6,605	$ 9,245

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - Jun. 30, 2015 - USD ($) $ in Millions	Total
Income Tax Disclosure [Line Items]
Deferred tax assets, net	$ 15.6
Research and development tax credit studies	10.5
Unrecognized tax benefits	3
Deferred Tax Assets, Valuation Allowance	$ 0.4
Overall effective tax rate, after discrete period adjustments	34.00%
Effective tax rate, before discrete period adjustment	36.60%
Research and Development Credits
Income Tax Disclosure [Line Items]
Tax credit carryforward, valuation allowance	$ 1.2
Expiring in 2019
Income Tax Disclosure [Line Items]
Tax Credit Carryforward, Amount	1.2
State
Income Tax Disclosure [Line Items]
Unrecognized tax benefits	0.2
Federal
Income Tax Disclosure [Line Items]
Unrecognized tax benefits	$ 2.8

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	May. 31, 2013	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	May. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option available for future grants			1,300,000
Tax payments, for net share settlement of share based award			$ 647,000	$ 1,190,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options			$ 17,500,000
Weighted average period			2 years 10 months 6 days
Approximate units outstanding			1,183,000		1,226,000
Performance Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approximate units of performance restricted stock granted			36,101
Approximate units outstanding			100,000
Maximum additional shares to be issued			100,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares withheld, for net share settlement of share based award			25,000
Tax payments, for net share settlement of share based award			$ 600,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share			$ 33.31
Total intrinsic value of options exercised			$ 13,200,000	$ 12,600,000
Number of options outstanding			1,133,000		1,641,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding			200,000
Unvested performance options			30,600
Unvested share, expected to vest			25,000
2013 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized	1,600,000
2014 Stock Repurchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding common stock repurchase program authorized amount						$ 30,000,000
Shares repurchased during period		1,500,000	0
Cost of shares repurchased		$ 19,600,000
Average cost of shares repurchased (in USD per share)		$ 13.16
Average price of shares repurchased (in USD per share)		$ 13.13
Remaining authorized repurchase amount			$ 7,600,000

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail) - 6 months ended Jun. 30, 2015 - Restricted Stock - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Total
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of Units outstanding, beginning of year	1,226
Number of Units, Granted	368
Number of Units, Released	(364)
Number of Units, Forfeited	(47)
Number of Units outstanding, end of year	1,183
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year	$ 13.23
Weighted Average Grant Date Fair Value, Granted	27.44
Weighted Average Grant Date Fair Value, Released	11.14
Weighted Average Grant Date Fair Value, Forfeited	15.70
Weighted Average Grant Date Fair Value, Units outstanding, end of year	$ 18.18
Aggregate intrinsic value at year end (in thousands)	$ 39,411

Stockholders' Equity - Summar47

Stockholders' Equity - Summary of the Company's Stock Options Activity (Detail) - Jun. 30, 2015 - Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Total
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, Options outstanding, beginning of year	1,641
Number of options, Granted	0
Number of options, Exercised	(500)
Number of options, Expired / terminated	(8)
Number of options, Options outstanding, end of year	1,133
Number of options, Options exercisable, end of year	1,101
Number of options, Options expected to vest, end of year	26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Options outstanding, beginning of year	$ 5.26
Weighted average exercise price, Granted	0
Weighted average exercise price, Exercised	4.96
Weighted average exercise price, Expired / terminated	8.71
Weighted average exercise price, Options outstanding, end of year	5.35
Weighted average exercise price, Options exercisable, end of year	5.37
Weighted average exercise price, Options expected to vest, end of year	$ 4.75
Weighted average remaining contractual life, Options outstanding (in years)	3 years 10 months 13 days
Weighted average remaining contractual life, Options exercisable (in years)	3 years 10 months 17 days
Weighted average remaining contractual life, Options expected to vest (in years)	3 years 7 months 10 days
Aggregate intrinsic value, Options outstanding	$ 31,685
Aggregate intrinsic value, Options exercisable	30,772
Aggregate intrinsic value, Options expected to vest	$ 750

Stockholders' Equity - Reported

Stockholders' Equity - Reported Share-Based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,679	$ 1,507	$ 3,223	$ 2,684
Cost of products sold and services delivered
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	89	65	159	88
Sales, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	925	948	1,858	1,658
Research and development expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 665	$ 494	$ 1,206	$ 938

Line of Credit - Additional Inf

Line of Credit - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Total availability under line of credit agreement	$ 10	$ 10
Letters of credit outstanding amount	3
Available borrowing under letter of credit	$ 7
Varying Interest on Line of credit agreement	LIBOR plus 1.5% or Prime less 0.75%
Maturity date of line of credit	Jul. 31, 2016
Maximum ratio of total liabilities to tangible net worth	1
Minimum required fixed coverage charge ratio	1.25
Period used for calculating ratios	12 months
Company's tangible net worth ratio	0.42
Fixed coverage charge ratio	2.81
Line of Credit | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Line of credit interest rate	1.50%
Line of Credit | Prime Rate
Debt Instrument [Line Items]
Line of credit interest rate	0.75%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2015Case	Sep. 30, 2011Case	Jun. 30, 2015USD ($)Lawsuit
Commitments and Contingencies Disclosure [Abstract]
Number of lawsuits against Company | Lawsuit			12
Number of active product liability cases | Case	13	55
Schedule of Commitments and Contingencies [Line Items]
Letters of credit outstanding amount			$ 3
Expiring May 2017
Schedule of Commitments and Contingencies [Line Items]
Letters of credit outstanding amount			2.7
Expiring January 2017
Schedule of Commitments and Contingencies [Line Items]
Letters of credit outstanding amount			0.3
Surety Bond
Schedule of Commitments and Contingencies [Line Items]
Bonds outstanding			2.4
Surety Bond | Expiring in July 2018
Schedule of Commitments and Contingencies [Line Items]
Bonds outstanding			2.2
Scenario, Forecast | Surety Bond
Schedule of Commitments and Contingencies [Line Items]
Bonds outstanding			$ 0.2

Commitments and Contingencies51

Commitments and Contingencies - Information Regarding the Company's Insurance Coverage (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2015USD ($)
2,004
Product Liability Contingency [Line Items]
Insurance Coverage	$ 2
Deductible Amount	0.1
Remaining Insurance Coverage	2
2,005
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	7
2,006
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	3.7
2,007
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	8
2,008
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.5
Remaining Insurance Coverage	0
2,009
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
2,010
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
2,011
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
Jan - Jun 2012
Product Liability Contingency [Line Items]
Insurance Coverage	7
Deductible Amount	1
Remaining Insurance Coverage	7
Jul - Dec 2012
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2,013
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2,014
Product Liability Contingency [Line Items]
Insurance Coverage	11
Deductible Amount	4
Remaining Insurance Coverage	11
2,015
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	5
Remaining Insurance Coverage	$ 10

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Officer - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Consulting
Related Party Transaction [Line Items]
Transaction expenses incurred by parent company	$ 65,000	$ 41,000	$ 112,000	$ 71,000
Outstanding payables due to related party	21,000		21,000		$ 8,000
Software Licensing and Subscription
Related Party Transaction [Line Items]
Quarterly software licensing fee	20,000
Deferred costs related to annual software subscription	$ 80,000		$ 80,000		$ 0

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Defined Benefit Plan Disclosure [Line Items]
Employee deferrals deemed vested percentage upon contribution			100.00%
Company's contributions to the plan	$ 300	$ 200	$ 600	$ 400
Company's expected contributions to the plan	$ 7		$ 23
Minimum
Defined Benefit Plan Disclosure [Line Items]
Deferral percentage of base salary			80.00%
Maximum
Defined Benefit Plan Disclosure [Line Items]
Deferral percentage of other compensation			100.00%

Segment Data - Additional Infor

Segment Data - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Segment	Jun. 30, 2014USD ($)
Segment Reporting [Abstract]
Number of reportable segments of company | Segment			2
Segment Reporting Information [Line Items]
Net sales	$ 46,713	$ 37,175	$ 91,475	$ 73,360
Gross margin	30,723	23,214	60,591	45,422
Sales, general and administrative	15,443	13,547	30,008	27,293
Research and development	5,906	3,455	10,464	7,061
Income from operations	9,374	6,212	20,119	11,068
Purchase of property and equipment			1,770	1,222
Purchase of intangible assets			201	109
Depreciation and amortization			1,362	2,267
Operating Segments
Segment Reporting Information [Line Items]
Product sales	43,755	36,268	86,598	71,781
Service revenue	2,958	907	4,877	1,579
Net sales		37,175	91,475	73,360
Cost of products sold	14,994	13,423	29,223	26,997
Cost of services delivered	996	538	1,661	941
Gross margin		23,214	60,591	45,422
Sales, general and administrative		13,547	30,008	27,293
Research and development		3,455	10,464	7,061
Income from operations	9,374	6,212	20,119	11,068
Purchase of property and equipment	1,346	423	1,770	1,222
Purchase of intangible assets	151	42	201	109
Purchase of property and equipment and intangible assets in connection with business acquisition	9,779	0	9,779	0
Depreciation and amortization	745	1,105		2,267
Operating Segments | TASER Weapons
Segment Reporting Information [Line Items]
Product sales	37,825	32,675	76,166	65,150
Service revenue	0	0	0	0
Net sales	37,825	32,675	76,166	65,150
Cost of products sold	11,278	10,663	22,359	21,581
Cost of services delivered	0	0	0	0
Gross margin	26,547	22,012	53,807	43,569
Sales, general and administrative	10,823	10,901	21,528	22,190
Research and development	1,077	793	2,267	1,610
Income from operations	14,647	10,318	30,012	19,769
Purchase of property and equipment	188	336	535	1,033
Purchase of intangible assets	35	42	81	109
Purchase of property and equipment and intangible assets in connection with business acquisition	0	0	0	0
Depreciation and amortization	556	990	1,086	2,068
Operating Segments | Axon
Segment Reporting Information [Line Items]
Product sales	5,930	3,593	10,432	6,631
Service revenue	2,958	907	4,877	1,579
Net sales	8,888	4,500	15,309	8,210
Cost of products sold	3,716	2,760	6,864	5,416
Cost of services delivered	996	538	1,661	941
Gross margin	4,176	1,202	6,784	1,853
Sales, general and administrative	4,620	2,646	8,480	5,103
Research and development	4,829	2,662	8,197	5,451
Income from operations	(5,273)	(4,106)	(9,893)	(8,701)
Purchase of property and equipment	1,158	87	1,235	189
Purchase of intangible assets	116	0	120	0
Purchase of property and equipment and intangible assets in connection with business acquisition	9,779	0	9,779	0
Depreciation and amortization	$ 189	$ 115	$ 276	$ 199

Business Acquisition (Details)

Business Acquisition (Details) - USD ($) $ in Thousands	May. 05, 2015	Jun. 30, 2015	Dec. 31, 2014
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill		$ 7,786	$ 2,206
Deferred income tax liabilities, net		$ (1,152)	$ (1,471)
MediaSolv Solutions Corporation
Business Acquisition [Line Items]
Consideration transferred	$ 8,792
Payments to acquire businesses, net	7,800
Contingent liability	1,000
Additional earn-out provisions and compensation adjustments	$ 4,000
Intangible assets, weighted average useful life (in years)	6 years 6 months
Acquisition transaction costs	$ 200
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable and other current assets	591
Inventory	35
Property and equipment	54
Intangible assets	4,145
Goodwill	5,580
Accounts payable and accrued liabilities	(403)
Deferred income tax liabilities, net	(1,057)
Deferred revenue	$ (153)

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Jul. 16, 2015	Aug. 31, 2015
Subsequent Event [Line Items]
Stock repurchased during period (in shares)		0.3
Stock repurchased during period, total cost		$ 7.6
Average cost of shares repurchased (in USD per share)		$ 25.86
Average price of shares repurchased (in USD per share)		$ 25.83
Tactical Safety Responses Limited (TSR)
Subsequent Event [Line Items]
Cash payments to acquire business	$ 4